L-carnitine treatment in patients with mild diastolic heart failure is associated with improvement in diastolic function and symptoms

Cardiology

Volumn 116, Issue 3, 2010, Pages 178-182

  Serati, Ali Reza ^a   Motamedi, Mohammad Reza ^a   Emami, Sepideh ^a   Varedi, Peyman ^b   Movahed, Mohammad Reza ^c  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

Antioxidant; Carnitine; Diastolic; Diastolic function; Diastology; Echocardiography; Heart failure; L Carnitine

Indexed keywords

CARNITINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DIASTOLIC HEART FAILURE; DYSPNEA; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART LEFT ATRIUM; HUMAN; MALE; PRIORITY JOURNAL; RELAXATION TIME;

ADULT; AGED; CARNITINE; DYSPNEA; ECHOCARDIOGRAPHY; FATTY ACIDS; FEMALE; HEART FAILURE, DIASTOLIC; HUMANS; IRAN; MALE; MIDDLE AGED; STROKE VOLUME; TREATMENT OUTCOME; VITAMIN B COMPLEX;

EID: 77954562244     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000318810     Document Type: Article

References (30)

1. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ: Burden of systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of the heart failure epidemic. JAMA 2003; 289: 194-202.
2. Pedersen F, Raymond I, Madsen LH, Mehlsen J, Atar D, Hildebrandt P: Echocardiographic indices of left ventricular diastolic dysfunction in 647 individuals with preserved left ventricular systolic function. Eur J Heart Fail 2004; 6: 439-447.
3. Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier OH, Taegtmeyer H: Metabolic gene expression in fetal and failing human heart. Circulation 2001; 104: 2923-2931.
4. Anand I, Chandrashekhan Y, De Giuli F, Pasini E, Mazzoletti A, Confortini R, Ferrari R: Acute and chronic effects of propionyl-L -carnitine on the hemodynamics, exercise capacity and hormones in patients with congestive heart failure. Cardiovasc Drugs Ther 1998;12: 291-299.
5. Investigators of the Study on Propionyl-L -carnitine in Chronic Heart Failure: Study on propionyl-L -carnitine in chronic heart failure. Eur Heart J 1999; 20: 70-76.
6. Pastoris O, Dossena M, Foppa P, Catapano M, Arbustini E, Bellini O, Dal Bello B, Minzioni G, Ceriana P, Barzaghi N: Effect of L -carnitine on myocardial metabolism: results of a balanced, placebo-controlled, double-blind study in patients undergoing open heart surgery. Pharmacol Res 1998; 37: 115-122.
7. Bartels GL, Remme WJ, Holwerda KJ, Kruijssen DA: Anti-ischaemic efficacy of L -propionylcarnitine -a promising novel metabolic approach to ischaemia? Eur Heart J 1996; 17: 414-420.
8. Bartels GL, Remme WJ, den Hartog FR, Wielenga RP, Kruijssen DA: Additional antiischemic effects of long-term L -propionylcarnitine in anginal patients treated with conventional antianginal therapy. Cardiovasc Drugs Ther 1995; 9: 749-753.
9. Bartels GL, Remme WJ, Pillay M, Schönfeld DH, Kruijssen DA: Effects of L -propionylcarnitine on ischemia-induced myocardial dysfunction in men with angina pectoris. Am J Cardiol 1994; 74: 125-130.
10. Singh RB, Niaz MA, Agarwal P, Beegum R, Rastogi SS, Sachan DS: A randomized, double-blind, placebo-controlled trial of L -carnitine in suspected acute myocardial infarction. Postgrad Med J 1996; 72: 45-50.
11. Iliceto S, Scrutinio D, Bruzzi P, D'Ambrosio G, Boni L, Di Biase M, Biasco G, Hugenholtz PG, Rizzon P: Effects of L -carnitine administration on left ventricular remodelling after acute anterior myocardial infarction: the L -carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial. J Am Coll Cardiol 1995; 26: 380-387.
12. Gasparetto A, Corbucci GG, De Blasi RA, Antonelli M, Bagiella E, D'Iddio S, Trevisani C: Influence of acetyl-L -carnitine infusion on hemodynamic parameters and survival of circulatory-shock patients. Int J Clin Pharmacol Res 1991; 11: 83-92.
13. Corsi C, Pollastri M, Marrapodi E, Leanza D, Giordano S, D'Iddio S: L -Propionylcarnitine effect on postexercise and postischemic hyperemia in patients affected by peripheral vascular disease. Angiology 1995; 46: 705-713.
14. Abhayaratna WP, Marwick TH, Smith WT, Becker NG: Characteristics of left ventricular diastolic dysfunction in the community: an echocardiographic survey. Heart 2006; 92: 1259-1264.
15. Engel AG, Angelini C: L -Carnitine deficiency of human skeletal muscle with associated lipid storage myopathy: a new syndrome. Science 1973; 179: 899-902.
16. Shug AL, Thomsen JH, Folts JD, Bittar N, Klein MI, Koke JR, Huth PJ: Changes in tissue levels of L -carnitine and other metabolites during myocardial ischemia and anoxia. Arch Biochem Biophys 1978; 187: 25-33.
17. Paulson DJ: L -Carnitine deficiency-induced cardiomyopathy. Mol Cell Biochem 1998; 180: 33-41.
18. Zaugg CE, Spaniol M, Kaufmann P, Bellahcene M, Barbosa V, Tolnay M, Buser PT, Krähenbühl S: Myocardial function and energy metabolism in L -carnitine-deficient rats. Cell Mol Life Sci 2003; 60: 767-775.
19. Silverman NA, Schmitt G, Vishwanath M, Feinberg H, Levitsky S: Effect of L -carnitine on myocardial function and metabolism following global ischemia. Ann Thorac Surg 1985; 40: 20-24.
20. Motterlini R, Samaja M, Tarantola M, Micheletti R, Bianchi G: Functional and metabolic effects of propionyl-L -carnitine in the isolated perfused hypertrophied rat heart. Mol Cell Biochem 1992; 116: 139-145.
21. Rodriguez B, Xiang H, McNeil T: Effect of L -carnitine treatment on lipid metabolism and cardiac performance in chronically diabetic rats. Diabetes 1988; 37: 1358-1364.
22. Bain MA, Milne RW, Evans AM: Disposition and metabolite kinetics of oral L -carnitine in humans. J Clin Pharmacol 2006; 46: 1163-1170.
23. Kerner J, Hoppel C: Fatty acid import into mitochondria. Biochim Biophys Acta 2000; 1486: 1-17.
24. Rosano GM, Vitale C, Sposato B, Mercuro G, Fini M: Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebocontrolled study. Cardiovasc Diabetol 2003; 2: 16.
25. Andreozzi GM: Propionyl L -carnitine: intermittent claudication and peripheral arterial disease. Expert Opin Pharmacother 2009; 10: 2697-2707.
26. Soukoulis V, Dihu JB, Sole M, Anker SD, Cleland J, Fonarow GC, Metra M, Pasini E, Strzelczyk T, Taegtmeyer H, Gheorghiade M: Micronutrient deficiencies an unmet need in heart failure. J Am Coll Cardiol 2009; 54: 1660-1673.
27. Investigators of the Study on Propionyl-L -Carnitine in Chronic Heart Failure: Study on propionyl-L -carnitine in chronic heart failure. Eur Heart J 1999; 20: 70-76.
28. Anand I, Chandrashekhan Y, De Giuli F, et al: Acute and chronic effects of propionyl-L -carnitine on the hemodynamics, exercise capacity, and hormones in patients with congestive heart failure. Cardiovasc Drugs Ther 1998; 22: 291-299.
29. Löster H, Miehe K, Punzel M, Stiller O, Pankau H, Schauer J: Prolonged oral L -carnitine substitution increases bicycle ergometer performance in patients with severe, ischemically induced cardiac insufficiency. Cardiovasc Drugs Ther 1999; 13: 537-546.
30. Rizos I: Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L -carnitine administration. Am Heart J 2000; 139:S120-S123.